SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)

Published:2015-02 Issue:2 Volume:10 Page:387-391
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ou Sai-Hong Ignatius,Moon James,Garland Linda L.,Mack Philip C.,Testa Joseph R.,Tsao Anne S.,Wozniak Antoniette J.,Gandara David R.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells;Suzuki;Mol Med Rep,2009

2. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth;Altomare;Oncogene,2005

3. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study;Garland;J Clin Oncol,2007

4. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM);Cedrés;Lung Cancer,2012

5. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids;Barbone;J Biol Chem,2008

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unleashing precision: A review of targeted approaches in pleural mesothelioma;Critical Reviews in Oncology/Hematology;2024-11

2. Malignant Pleural Mesothelioma: Socioeconomic and Clinical Aspects;Current Cancer Therapy Reviews;2024-07-23

3. NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity;npj Precision Oncology;2024-06-15

4. The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition;Translational Oncology;2024-05

5. Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice;Clinical and Experimental Medicine;2024-04-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3